NIH Researchers Find an Existing Drug Can Treat a Rare Multi-Organ Autoimmune Disorder
Autoimmune polyendocrine syndrome type 1, or APS-1, is one of medicine's more striking examples of how a single gene defect can cascade into widespread immune dysregulation. Caused by mutations in the AIRE gene, which normally helps the thymus teach developing immune cells to recognize and spare the body's own tissues, APS-1 leads to attacks on multiple organs at once. The classic triad involves hypoparathyroidism, Addison's disease, and chronic mucocutaneous candidiasis, meaning persistent fungal infections of the mouth, nails, and skin, but the condition can also affect the gut, lungs, liver, eyes, skin pigmentation, and other systems. It is rare, autosomal recessive, and for most of its history has been managed symptom by symptom without any disease-modifying treatment targeting its root cause.
Researchers at the National Institute of Allergy and Infectious Diseases, part of NIH, reported in a study published in the New England Journal of Medicine that ruxolitinib, a drug already approved for several blood cancers and inflammatory conditions, produced meaningful clinical remission in five patients with APS-1. The findings, announced publicly in May 2024, offer the first real signal that a single immunological intervention might address the broad, multi-system nature of the disease.
The scientific rationale centers on interferon-gamma, an immune signaling molecule found at abnormally high levels in people with APS-1. AIRE deficiency appears to trigger a state of persistent interferon-gamma overdrive, which in turn activates downstream inflammatory pathways via a signaling cascade called JAK-STAT. Ruxolitinib works by inhibiting Janus kinase proteins, the molecular switches that relay interferon-gamma signals into the cell nucleus. By shutting off this relay, the drug quiets the downstream inflammation without broadly suppressing the immune system in the way that traditional immunosuppressants do.
The clinical results in the five patients treated were striking in their breadth. Patients experienced remission of alopecia, oral candidiasis, nail dystrophy, gastritis, enteritis, arthritis, a Sjogren's-like syndrome, urticaria, and thyroiditis. Laboratory values normalized, and no serious adverse effects from ruxolitinib were identified. The researchers also observed that T-cell-derived interferon-gamma levels dropped and that the inflammatory marker CXCL9 normalized during treatment.
Ruxolitinib is not a cure, and patients would likely need ongoing treatment to maintain its benefits, similar to how it is used in other conditions. The NIH team emphasizes that this was a small, open-label study, and that a larger, more diverse patient population will need to be studied to confirm safety and efficacy over the long term. A separate group published similar findings in three additional patients treated for at least 30 months, with good tolerance and no significant adverse events, adding further encouragement. For families affected by APS-1, who have often faced years of managing individual complications in isolation, the prospect of a treatment that addresses multiple manifestations simultaneously represents a fundamental shift in how the disease might one day be approached.